Abstract
Radiation therapy is a widely used treatment for locally advanced non-small cell lung cancer, as well as for a variety of other thoracic malignancies. Radiation induced lung injury (RILI) refers to any lung-related change resulting from this treatment. From a clinical standpoint, RILI is separated into two distinct syndromes: an acute pneumonitis beginning 2-10 weeks following RT and a more indolent fibrotic process, presenting months after initial exposure. A variety of factors have been identified that are associated with an increased risk of developing clinically significant RILI. These include treatment-related factors (dose and schedule of radiation, volume of lung irradiated, concurrent use of chemotherapy) and patient-related factors (age, gender, smoking status, presence of pre-existing lung disease). New insights into the mechanisms of radiation induced lung injury have been uncovered, and these findings have led to the development of novel strategies for the prevention and treatment of this complication. In this review, we will discuss the clinical manifestations and risk factors of RILI, and focus on recent advances in its pathogenesis and treatment.
Keywords: Radiation pneumonitis, radiotherapy, lung cancer
Current Respiratory Medicine Reviews
Title: Radiation-Induced Lung Injury Following Therapy for Thoracic Malignancy
Volume: 1 Issue: 3
Author(s): Ross K. Morgan, Lisa A. Kachnic and Ross Summer
Affiliation:
Keywords: Radiation pneumonitis, radiotherapy, lung cancer
Abstract: Radiation therapy is a widely used treatment for locally advanced non-small cell lung cancer, as well as for a variety of other thoracic malignancies. Radiation induced lung injury (RILI) refers to any lung-related change resulting from this treatment. From a clinical standpoint, RILI is separated into two distinct syndromes: an acute pneumonitis beginning 2-10 weeks following RT and a more indolent fibrotic process, presenting months after initial exposure. A variety of factors have been identified that are associated with an increased risk of developing clinically significant RILI. These include treatment-related factors (dose and schedule of radiation, volume of lung irradiated, concurrent use of chemotherapy) and patient-related factors (age, gender, smoking status, presence of pre-existing lung disease). New insights into the mechanisms of radiation induced lung injury have been uncovered, and these findings have led to the development of novel strategies for the prevention and treatment of this complication. In this review, we will discuss the clinical manifestations and risk factors of RILI, and focus on recent advances in its pathogenesis and treatment.
Export Options
About this article
Cite this article as:
Morgan K. Ross, Kachnic A. Lisa and Summer Ross, Radiation-Induced Lung Injury Following Therapy for Thoracic Malignancy, Current Respiratory Medicine Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339805774597992
DOI https://dx.doi.org/10.2174/157339805774597992 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preparation and Surface Modification of Polymeric Nanoparticles for Drug Delivery: State of the Art
Recent Patents on Drug Delivery & Formulation Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design Leveraging Structural Diversity and Allosteric Regulatory Mechanisms of Protein Kinases in the Discovery of Small Molecule Inhibitors
Current Medicinal Chemistry Dyspnea in Cancer Patients: A Well-Known and Neglected Symptom
Reviews on Recent Clinical Trials microRNAs Downregulation in Cancer is Associated with Guanine Enrichment in the Terminal Loop Sequences of their Precursors
MicroRNA Current Therapeutic Leads for the Treatment of Melanoma: Targeted Immunotherapy in the Post-genomic Era
Current Molecular Pharmacology Patent Review
Combinatorial Chemistry & High Throughput Screening Targeting Inhibitor of Apoptosis Proteins (IAPs) for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Molecular Imaging in Optical Coherence Tomography
Current Molecular Imaging (Discontinued) Editorial (Thematic Issue: The Thoracic Space: An Amazing Pandora’s Box!)
Current Respiratory Medicine Reviews Chemical Advances in Therapeutic Application of Exosomes and Liposomes
Current Medicinal Chemistry Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo
Current Drug Metabolism Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery MUC Glycoproteins: Potential Biomarkers and Molecular Targets for Cancer Therapy
Current Cancer Drug Targets The Application of the RNA Interference Technologies for KRAS: Current Status, Future Perspective and Associated Challenges
Current Topics in Medicinal Chemistry Isoform-Selective PI3K Inhibitors for Various Diseases
Current Topics in Medicinal Chemistry Atomic Force Microscopy: The Characterisation of Amyloid Protein Structure in Pathology
Current Topics in Medicinal Chemistry Radiolabelled Regulatory Peptides for Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry Pentapeptides as Minimal Functional Units in Cell Biology and Immunology
Current Protein & Peptide Science ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy
Current Pharmaceutical Design